NCT06066138 2026-03-11
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
National Institutes of Health Clinical Center (CC)
Amgen
Boehringer Ingelheim
Memorial Sloan Kettering Cancer Center
Fate Therapeutics
Hoffmann-La Roche